Matches in Nanopublications for { ?s ?p "[We hypothesized that combined CDKN1A-TP53 loss would make bladder cancer sensitive to combined treatment with gemcitabine and Chk1 inhibitor.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- NP1233057.RAf9Rn6iCXd2hcrRliTo9oYLYj5fnYSlyQx-dhlxFrG-I130_assertion description "[We hypothesized that combined CDKN1A-TP53 loss would make bladder cancer sensitive to combined treatment with gemcitabine and Chk1 inhibitor.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233057.RAf9Rn6iCXd2hcrRliTo9oYLYj5fnYSlyQx-dhlxFrG-I130_provenance.
- NP1233060.RAcEPvl8qiso5B3SdOaZHnPTVkS48lbUGtk9Xk4ERgXD0130_assertion description "[We hypothesized that combined CDKN1A-TP53 loss would make bladder cancer sensitive to combined treatment with gemcitabine and Chk1 inhibitor.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233060.RAcEPvl8qiso5B3SdOaZHnPTVkS48lbUGtk9Xk4ERgXD0130_provenance.
- NP1233059.RAryl5A1S5ncyRNffyyyC54y6Hy3707S7yDKikrtCIHsc130_assertion description "[We hypothesized that combined CDKN1A-TP53 loss would make bladder cancer sensitive to combined treatment with gemcitabine and Chk1 inhibitor.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233059.RAryl5A1S5ncyRNffyyyC54y6Hy3707S7yDKikrtCIHsc130_provenance.
- NP1233061.RAoh2tXlen0jhlB0SsmdYAfSxua37rsLXtL_XuEwby5ek130_assertion description "[We hypothesized that combined CDKN1A-TP53 loss would make bladder cancer sensitive to combined treatment with gemcitabine and Chk1 inhibitor.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233061.RAoh2tXlen0jhlB0SsmdYAfSxua37rsLXtL_XuEwby5ek130_provenance.